NCT05559879View on ClinicalTrials.gov

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 20, 2023

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Gynecologic CancerCarcinomaUterine CancerEndometrial Cancer
Interventions
DRUG

Cabo + Dostarlimab

Combination of standard dose of cabozantinib and 500 mg dostarlimab for first 4 cycles followed by standard dose of cabozantinib and 1000 mg of dostarlimab until 2 years of treatment

Trial Locations (1)

35294

RECRUITING

O'Neal Comprehensive Cancer Center at UAB, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER